

RECEIVED

OCT 23 2001

TECH CENTER 1600/2900

MAIN TELEPHONE
(312) 782-0600
MAIN FAX
(312) 782-7711

RECEIVED
TECH CENTER 1600/2900
OCT 18 PM 1:08

MAYER, BROWN & PLATT

190 SOUTH LA SALLE STREET
CHICAGO, ILLINOIS 60603-3441

JOSEPH A. MAHONEY
DIRECT DIAL (312) 701-8979
DIRECT FAX (312) 706-8530
jamahoney@mayerbrown.com

October 17, 2001

VIA HAND DELIVERY

Commissioner of Patents & Trademarks
Group Art Unit 1619
Washington, D.C. 20231


Re: United States Patent Application
Serial Number: 09/639,289
Entitled: STABLE COMPOSITION FOR INHALATION
THERAPY COMPRISING DELTA-9-
TETRAHYDROCANNABINOL IN A
SEMI-AQUEOUS SOLVENT THEREFORE
Our Reference: 01895284

Dear Sirs:

Enclosed please find a copy of the Patent Assignment and Revocation and Power of Attorney which we have forwarded to the United States Patent and Trademark Office, Assignment Branch for recordation.

Please forward any future correspondence regarding the above-identified patent application to the undersigned.

Respectfully submitted,



Joseph A. Mahoney

Enclosures

CHARLOTTE CHICAGO COLOGNE FRANKFURT HOUSTON LONDON

LOS ANGELES NEW YORK PALO ALTO PARIS WASHINGTON

INDEPENDENT MEXICO CITY CORRESPONDENT: JAUREGUI, NAVARRETE, NADER Y ROJAS

1099154.1 101701 1428C 01895284

Attorney Docket No. 01895284

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No: 09/639,289)
Filed: August 15, 2000)
For: STABLE COMPOSITION FOR)
INHALATION THERAPY COMPRISING)
DELTA-9-TETRAHYDROCANNABINOL)
AND SEMIQUEOUS SOLVENT)
THEREFOR)

#6
HKD
10/24/01
RECEIVED
TECH CENTER 1600/2900
01 OCT 18 PM 1:08

REVOCATION AND APPOINTMENT OF POWER OF ATTORNEY

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Unimed Pharmaceuticals, Inc., the owner by assignment, of the above-identified patent, hereby revokes all previous Powers of Attorney and appoints Robert J. Depke (Reg. No. 37,607), Douglas M. Eveleigh (Reg. No. 43,426), Joseph A. Mahoney (Reg. No. 38,956) Susan D. Reinecke (Reg. No. 40,198), Robert S. Rigg (Reg. No. 36,991), Deborah Schavey Ruff (Reg. No. 33,770), Donald W. Rupert (Reg. No. 29,974), Daniel H. Shulman (Reg. No. P45,106), Richard A. Speer (Reg. No. 17,930), Steven G. Steger (Reg. No. 40,185), Thomas R. Stiebel (Reg. No. P48,682), Wayne L. Tang (Reg. No. 36,028), David M. Thimmig (Reg. No. 36,034), and Michael O. Warnecke (Reg. No. 24,345), all of the law firm of Mayer, Brown & Platt located at 190 South LaSalle Street, Chicago, Illinois

1093489.1 81301 1100C 01736241

60603-3441, jointly and each of them separately, as its attorneys and attorney, with full power of delegation, substitution and revocation to transact all business in the Patent and Trademark Office connected herewith.

Please address all further correspondence and telephone calls in this application to:

Phone: (312) 701-8979 - Facsimile: (312) 701-8530.

Signed in the City of Deerfield, the State of Illinois, this
28 day of August, 2001.

BY: 

NAME: Jean-Louis Anspach

TITLE: President and CEO

Unimed Pharmaceuticals, Inc.

1093489.1 81301 1100C 01736241

- 2 -

ASSIGNMENT

Roxane Laboratories, Inc. a corporation of Delaware
1809 Wilson Road
Columbus, Ohio 43235 ("Assignor")

hereby assigns and transfers, under the conditions set forth below, to:

Unimed Pharmaceuticals, Inc. a corporation of Delaware
4 Parkway North
Deerfield, Illinois 60015-2544 ("Assignee")

its entire right, title and interest in and to any and all improvements which are disclosed in the application for United States Letters Patent which is entitled:

STABLE COMPOSITION FOR INHALATION THERAPY COMPRISING DELTA-9-TETRAHYDROCANNABINOL AND SEMIAQUEOUS SOLVENT THEREFOR

which was filed on August 15, 2000 with the United States Patent and Trademark Office, and accorded Serial Number 09/639,289, claiming priority from United States Provisional Application Serial Number 60/150,023 filed August 20, 1999, and in and to said application, all divisional and continuing applications, all continuations-in-part, extensions or substitutions and all other applications for United States Letters Patent which have been or shall be filed in the United States on any of said improvements, and in and to all original and reissued and re-examined patents which have been or shall be issued in the United States on said improvements;

Agrees said Assignee may apply for and receive United States Letters Patent for said improvements in its own name, and that, when requested, without charge to but at the expense of said Assignee, to carry out in good faith the intent and purpose of this assignment, Assignor will execute all divisional, continuing, continuations-in-part, extensions, substitute, re-examination, reissue, and all other patent applications on any and all said improvements, execute all rightful oaths, assignments, powers of attorney and other papers, communicate to said Assignee, all facts known to the undersigned relating to said improvements and the history thereof, generally do everything possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent protection in the United States for said improvements and for vesting title to said improvements within the United States and all United States applications for United States patents and all United States patents on said improvements in said Assignee;

Covenants with said Assignee that no assignment, grant mortgage license or other agreement affecting the rights and property herein conveyed has been made to others by

Assignor, and that full right to convey the same as herein expressed is possessed by Assignor; and

States that, to the best of its knowledge, there are no liens, licenses, encumbrances, claims, litigation (other than Civil Action No. C2-00-0125, J.L.G., filed in the U.S.D.C., S.D. Ohio), patent interferences (except as Assignee may have initiated) or oppositions pending with respect thereto, and further that the pending application identified above is in good standing at the United States Patent and Trademark Office and has not been abandoned.

This Assignment is conditioned upon the timely payment of all amounts specified in Paragraph 3 of the Confidential Settlement Agreement and Mutual Release between Assignor and Assignee effective April 13, 2001.

ROXANE LABORATORIES, INC.

By: Werner Gerstenberg
Werner Gerstenberg
President and Chief Operating Officer

Date: 07/03/01